VTYX - long - catalysts and gap - amazing R/R
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. Its lead product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
This is not a financial advice!
Recent block buy
Upcoming catalyst end of March 2024
Low float of 44.47M
Short float 11.20%
Keep an eye on 2.80 level - needs to get broken for a further upmove.
SL under 1.8
Potenential gap fill: TP approx. 14 -15
Most info on the chart.
Trade carefully!
This is not a financial advice!
Recent block buy
Upcoming catalyst end of March 2024
Low float of 44.47M
Short float 11.20%
Keep an eye on 2.80 level - needs to get broken for a further upmove.
SL under 1.8
Potenential gap fill: TP approx. 14 -15
Most info on the chart.
Trade carefully!
Komentarz:
uhh it's getting hot
Transakcja zamknięta: osiągnięto wyznaczony cel:
booom what a trade!